Results of this study suggest that the APOE ɛ4 allele can modulate both the clinical expression and the biomarkers of Alzheimer disease in a genetic form of the disease, such as in Down syndrome. This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.